EU Approves Sanofi's Cenrifki, First Disability-Targeting Medicine for SPMS
SNY is trading near its 52-week low of $40.89 (1.9% above the low) on elevated volume (2.1× avg).
Summary
Sanofi's Cenrifki (tolebrutinib) has received European Commission approval for secondary progressive multiple sclerosis (SPMS) without relapses. This marks the first disability-targeting medicine for this debilitating condition, addressing a significant unmet medical need. The approval follows a positive opinion from the European Medicines Agency's CHMP in April. This regulatory win expands Sanofi's pipeline and revenue potential in the neurology space. Sanofi expects to launch Cenrifki in Germany this year.
At the time of this announcement, SNY was trading at $41.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.2B. The 52-week trading range was $40.89 to $52.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.